(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes - 2Ukraine to get up to 100 French-made Rafale fighter jets
- 3German foreign minister heads to China to talk rare-earth exports
- 4Los Angeles County sees significant uptick in norovirus cases, officials say
- 5The Best Web-based Courses for Expertise Improvement
- Step by step instructions to Explore Assessment Ramifications of Disc Rates
- How do my eyes adjust to the dark and how long does it take?
- The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- Hot Electric Vehicles for 2023
- How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- Where America’s CO2 emissions come from – what you need to know, in charts
- Striking American and European television Projects: A Survey
- New science points to 4 distinct types of autism
- Pfizer says patient dies after receiving hemophilia drug in trial
